Core Viewpoint - Recently, Kefu Medical Technology Co., Ltd. announced plans to issue H-shares and list on the Hong Kong Stock Exchange to accelerate its global strategy and enhance overseas business capabilities [1][2]. Group 1: Company Strategy - Kefu Medical aims to enhance its brand image and international presence through the issuance of H-shares and listing on the Hong Kong Stock Exchange [2][5]. - The company plans to engage with intermediaries to discuss the specifics of the H-share listing, although details are yet to be finalized [2][3]. - The H-share listing is part of a broader strategy to support internationalization, improve capital operation efficiency for cross-border mergers and acquisitions, and strengthen global brand influence [5]. Group 2: Market Environment - The current national policy supports companies going global, making the Hong Kong listing aligned with policy directions and beneficial for international development [5]. - The Hong Kong market is characterized by high internationalization, providing a quality financing platform for companies [5]. Group 3: Overseas Business Development - Kefu Medical is committed to internationalization as a key strategic direction, combining organic growth with external acquisitions to enhance its overseas business layout [5]. - The company has successfully completed acquisitions of Huazhou and Ximaner in the first half of the year, which have effectively supplemented its overseas business resources [5]. Group 4: Technological Integration - Kefu Medical is actively promoting the integration of artificial intelligence (AI) with home medical devices, aiming to enhance the precision and intelligence of products such as dynamic blood glucose meters, blood pressure monitors, fetal heart rate monitors, and hearing aids [6].

Key Points Summary of Kefu Medical Conference Call Company Overview - **Company**: Kefu Medical - **Industry**: Medical Devices Core Insights and Arguments 1. **Impact of Online Business Adjustments**: Kefu Medical's revenue and profit remained stable year-on-year in Q2 2025 despite adjustments in online business, with core product strategies proving effective [2][3][4] 2. **Product Performance**: The company reported strong market performance for its respiratory machines and dual glucose-uric acid test strips, with the latter achieving the highest sales in its category [3][4] 3. **New Product Launch**: A bone conduction hearing aid is set to launch in September 2025, developed in collaboration with Tencent to enhance product competitiveness [2][6] 4. **O2O Business Growth**: Rapid growth in the O2O restaurant business was noted, with expectations for the O2O medical device category to reach 6 billion this year [3][4] 5. **H Share Issuance**: Kefu Medical plans to issue H shares to support international expansion and acquisitions, with a focus on reducing dilution impact on A shares [2][5][9] 6. **Acquisition of Himala**: The acquisition of Himala, Hong Kong's largest medical device chain, aims to enhance market presence and product quality, with Himala generating approximately 200 million HKD in sales [2][8][19] 7. **International Strategy**: The company is targeting high-quality brands and channels in Europe and Southeast Asia for future acquisitions, leveraging China's competitive manufacturing capabilities [4][10][29] Additional Important Information 1. **Financial Performance**: Kefu Medical's overseas revenue is expected to exceed 100 million in H1 2025, with a projected total of over 300 million for the year, marking significant growth compared to previous years [4][13] 2. **Profit Margin Outlook**: The acquisition of Himala is anticipated to improve profit margins from 10% to over 16% through supplier adjustments and product restructuring [14][19] 3. **Market Dynamics**: The competitive landscape for blood glucose and rehabilitation products is intensifying, with ongoing price wars and innovation among major players [26] 4. **Sales Channel Performance**: Online sales accounted for nearly 70% of total sales in H1 2025, with Douyin showing the fastest growth among platforms [24][25] 5. **Future Growth Areas**: The company expects significant improvements in health monitoring categories, particularly in home testing and temperature measurement products [22][23] This summary encapsulates the key points discussed in the conference call, highlighting Kefu Medical's strategic initiatives, product performance, and market outlook.

Group 1: Company Announcements - Kefu Medical announced plans for an IPO in Hong Kong to enhance its global strategy and overseas business capabilities, covering five major areas including health monitoring and rehabilitation [1] - Xingchen Technology is planning to issue H-shares and apply for a listing on the Hong Kong Stock Exchange to leverage international capital markets for its AI SoC solutions across various smart applications [3] - Lianqi Technology submitted its listing application to the Hong Kong Stock Exchange, positioning itself as the largest supplier of memory interconnect chips with a market share of 36.8% in 2024 [4] Group 2: Regulatory Actions - The Hong Kong Securities and Futures Commission has imposed bans on five former executives of Qifeng International for periods ranging from five to ten years, highlighting strict regulatory oversight on corporate governance [2] Group 3: Market Performance - The Hang Seng Index closed at 24,139.57, with a gain of 0.46% on July 11, while the Hang Seng Tech Index and the National Enterprises Index also saw increases of 0.61% and 0.22% respectively [5]

Core Viewpoint - The company, KeFu Medical, is planning to issue H-shares and list on the Hong Kong Stock Exchange to accelerate its global strategy and enhance its overseas business capabilities and brand recognition [1][4]. Group 1: Company Overview - KeFu Medical is a comprehensive personal health management enterprise engaged in the research, production, sales, and service of medical devices, covering five major areas: health monitoring, rehabilitation aids, respiratory support, medical care, and traditional Chinese medicine therapy [3]. - The company's main brand "KeFu" includes sub-brands such as "JianEr Hearing," "JiRui Medical," "BeiBeiJia," "YanBenShu," and "YangLiDe" [3]. Group 2: Financial Performance - In the first quarter of this year, KeFu Medical reported a revenue of approximately 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of about 91.43 million yuan, down 9.68% year-on-year [6]. - The company's revenue from overseas markets was approximately 5.91 million yuan in 2024, accounting for only 1.98% of total revenue, indicating that its overseas business is still in the cultivation stage [4]. Group 3: Strategic Intentions - The decision to list on the Hong Kong Stock Exchange aligns with national policies supporting companies going global and aims to enhance the company's international development [4]. - The company has completed acquisitions of Shanghai Huazhou and Ximan Na, which are expected to strengthen its overseas business resources [5]. - Future overseas acquisitions will focus on companies that can supplement product lines or enhance technological capabilities, as well as those with established distribution networks or brand influence [5].

Investment Rating - The report maintains a "Buy" rating for the agriculture, forestry, animal husbandry, and fishery sector [4] Core Viewpoints - Recent policy guidance has led to a rapid decline in post-slaughter weight, allowing for a rebalancing of volume and price, with positive expectations for pig prices [3] - The long-term perspective indicates that the bottom of the production capacity cycle is becoming clearer, suggesting a potential long-term profit upturn for the sector [3] - The report highlights investment opportunities in various segments, including pig farming, feed, and planting chains, as well as the pet food sector [3] Summary by Sections Pig Farming Sector - In June, 13 listed pig companies collectively slaughtered 16.2681 million pigs, a month-on-month increase of 2.65% and a year-on-year increase of 47.55% [2][13] - The average selling price of pigs decreased by approximately 3% month-on-month and about 20% year-on-year, with prices ranging from 13.23 to 15.57 yuan/kg [14][15] - The average weight of slaughtered pigs in June was 125.06 kg, down 0.77 kg from May, indicating a trend towards reducing weight [17] Market Dynamics - The national average price for live pigs was 14.81 yuan/kg as of July 11, reflecting a week-on-week decline of 3.52% [28] - The demand for pork is weakening due to high temperatures affecting consumption and rising storage costs, leading to a gradual loosening of supply-demand dynamics [28] Investment Recommendations - The report recommends focusing on leading companies such as Muyuan Foods, Wens Foodstuff, and Juxing Agriculture, as well as companies in the feed and animal health sectors like Haida Group and Ruipu Biological [3] - In the planting chain, opportunities are highlighted for companies like Suqian Agricultural Development and Beidahuang [3] Other Segments - The pet food industry is experiencing growth, with increasing recognition of domestic brands and continuous growth of leading companies [3]

Core Viewpoint - Kefu Medical (301087) reported stable overall operations in Q2, with steady market demand and notable growth in specific product lines [1] Group 1: Business Performance - The company indicated that its overall business operations remained normal during the second quarter [1] - Market demand for Kefu Medical's products is relatively stable [1] Group 2: Product Performance - Growth was particularly strong in the hearing aid business, home testing reagents (such as Helicobacter pylori testing and fertility testing), dressing products, and adult care products [1] - Kefu's self-developed ventilator has performed exceptionally well, currently ranking first in sales on the Douyin platform [1]

Group 1: Company Performance - The overall operating status in Q2 remained stable, with strong growth in hearing aids, home testing reagents, dressings, and adult care products [2] - The self-developed ventilator achieved outstanding performance, ranking first in sales on Douyin, with industry-leading noise reduction and performance [3] - The blood glucose and uric acid integrated machine showcases a unique dual-testing technology, reducing user burden and medical costs [3] Group 2: Hong Kong Listing Rationale - The current national policy supports companies "going global," making the Hong Kong listing aligned with policy direction and beneficial for international development [4] - The Hong Kong market offers a high degree of internationalization, providing a quality financing platform for companies [4] - Establishing an H-share platform is a strategic move to enhance overseas business capabilities and improve cross-border M&A efficiency [4] Group 3: International Business Strategy - The company aims for internationalization through a combination of organic growth and acquisitions, continuously enhancing its overseas business layout [5] - Significant investments are being made in overseas markets, with local product development and registration efforts underway [5] - The company completed acquisitions of Huazhou and Ximan in the first half of the year, enhancing overseas business resources [5] Group 4: Acquisition Projects - Huazhou, established in 2002, is a leading manufacturer of pressure-sensitive adhesive products, with over 60% of its revenue from overseas [6] - Ximan, with nearly 40 years of experience, operates retail medical device centers and will help the company penetrate the Hong Kong market [7] - Future acquisitions will focus on companies that can enhance product lines or technical capabilities and those with established distribution networks or brand influence [7] Group 5: Hearing Aid Business Outlook - The hearing aid business is focused on improving operational quality and has seen some improvement in profitability [7] - The Chinese hearing aid market has significant growth potential but faces challenges such as low public awareness and usage rates [7] - The company plans to provide comprehensive services for hearing-impaired individuals, leveraging its core competitive advantage in personalized solutions [7]

Core Viewpoint - Kefu Medical has initiated preparations for issuing H-shares and listing on the Hong Kong Stock Exchange, indicating a strategic move to enhance its capital and market presence [1]. Company Operations - Kefu Medical, established in 2009, specializes in the research, production, sales, and service of home medical devices, covering various fields such as health monitoring and rehabilitation aids [2]. - The company faces increasing operational pressure due to fierce competition in the home medical device market, with traditional giants like Yuyue Medical dominating the market alongside emerging companies leveraging innovative designs and marketing strategies [2][3]. Product Structure - Despite a diverse product line, Kefu Medical's market competitiveness in certain segments, particularly health monitoring devices, is under pressure from competitors like Sanofi and Omron, which have superior technology and brand reputation [3]. - The company struggles with product homogeneity, lacking standout products that can differentiate it in the market [3]. Financial Performance - Kefu Medical's revenue for 2024 was 2.983 billion yuan, a modest increase of 4.53% year-on-year, indicating a slowdown compared to previous years [4][5]. - The net profit for 2024 was 312 million yuan, up 22.6% year-on-year, primarily due to cost control rather than strong core business growth [4]. - In Q1 2025, the company reported a revenue decline of 8.59% year-on-year, with net profit decreasing by 9.68% [4]. Financial Metrics - The gross profit margin improved to 51.86% in 2024, achieved through product structure optimization and cost reduction [6]. - The sales expense ratio was high at 27.34%, significantly above the industry average, impacting profitability [6]. - Accounts receivable reached 485 million yuan, up 11.52% from the beginning of the year, while inventory increased by 10.16% to 683 million yuan, raising concerns about cash flow efficiency [6][7]. Management Team - Kefu Medical's management team possesses extensive experience in the medical device industry, but there is a need for new energy and knowledge in emerging technologies like AI and IoT to keep pace with industry advancements [8]. - The upcoming Hong Kong listing necessitates enhanced international perspectives and capital operation capabilities from the management team [8]. IPO in Hong Kong - The Hong Kong listing presents both opportunities and challenges for Kefu Medical, including access to a broader investor base and increased capital for R&D and market expansion [9]. - The company must improve its governance and transparency to meet the stringent disclosure requirements of the Hong Kong market [9]. - Kefu Medical needs to demonstrate strong performance and growth potential to attract investor interest, while also navigating risks such as currency fluctuations and regulatory differences [9].

Group 1 - The company, KeFu Medical, has authorized its management to initiate the process for overseas issuance of shares (H-shares) and prepare for listing on the Hong Kong Stock Exchange [1]

证券代码：301087 证券简称：可孚医疗 公告编号：2025-042 可孚医疗科技股份有限公司 第二届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 可孚医疗科技股份有限公司（以下简称"公司"）第二届董事会第十五次会 议于 2025 年 7 月 11 日以电话方式发出会议通知，会议于 2025 年 7 月 11 日下午 3:00 以现场与通讯表决相结合的方式在公司六楼会议室召开。会议应出席董事 7 人，实际出席董事 7 人（其中独立董事刘爱明、温志浩、宁华波以通讯方式出席）， 公司监事、高级管理人员列席了会议。本次会议由董事长张敏先生主持。会议的 召集和召开符合《中华人民共和国公司法》等法律法规和《公司章程》的有关规 定。 二、董事会会议审议情况 与会董事对本次会议需审议的议案进行了充分讨论，审议通过了如下议案： 审议通过《关于授权公司管理层启动公司境外发行股份（H 股）并在香港 联合交易所有限公司上市相关筹备工作的议案》 特此公告。 可孚医疗科技股份有限公司董事会 2025 年 7 月 11 日 2 具体内容详 ...